Cover Image
市場調查報告書

高血壓 : 開發平台分析

Hypertension - Pipeline Review, H1 2016

出版商 Global Markets Direct 商品編碼 232783
出版日期 內容資訊 英文 564 Pages
訂單完成後即時交付
價格
Back to Top
高血壓 : 開發平台分析 Hypertension - Pipeline Review, H1 2016
出版日期: 2016年06月08日 內容資訊: 英文 564 Pages
簡介

高血壓指的是動脈的血壓持續上升的狀態。包含體內荷爾蒙、水分、鹽分濃度、腎臟、神經系統或血管狀態等各種因素在內皆會影響血壓。大部分人即使血壓數值高到危險的程度也不會顯露出高血壓的症狀。即使有些人在早期高血壓便有頭部隱隱作痛、頭暈、比一般更容易或流出更多鼻血但典型的患者常是即使高血壓加劇也沒有上述症狀。

本報告提供高血壓的治療藥開發平台現狀及最新更新的各開發階段比較分析,提供您最新的新聞和發表,加上企業和研究機關開發中的治療藥,治療藥評估,後期階段及中止的計劃等相關資訊。

簡介

  • 調查範圍

高血壓 概要

治療藥的開發

  • 開發中產品;概要
  • 開發中產品;比較分析

企業開發中的治療藥

大學/機關研究中的治療藥

開發中產品概況

  • 後期階段的產品
  • 臨床階段的產品
  • 初期階段的產品

企業開發中的產品

大學/機關研究中的產品

治療藥的開發企業

  • A1M Pharma AB
  • AbbVie Inc.
  • Ache Laboratorios Farmaceuticos S/A
  • Actelion Ltd
  • Afferent Pharmaceuticals, Inc.
  • Allergan Plc
  • Alnylam Pharmaceuticals, Inc.
  • Anacor Pharmaceuticals, Inc.
  • APT Therapeutics, Inc.
  • Arena Pharmaceuticals, Inc.
  • Ascendis Pharma A/S
  • AVEO Pharmaceuticals, Inc.
  • Bayer AG
  • Bial - Portela & Ca, S.A.
  • Bio-inRen
  • BioRestorative Therapies, Inc.
  • Bristol-Myers Squibb Company
  • Cellceutix Corporation
  • Celsion Corporation
  • Celtaxsys, Inc.
  • Chong Kun Dang Pharmaceutical Corp.
  • CJ HealthCare Corp.
  • Complexa, Inc.
  • Conatus Pharmaceuticals Inc.其他

治療藥的評估

  • 單劑產品
  • 組合產品
  • 標的別
  • 各作用機制
  • 各給藥途徑
  • 各分子類型

藥物簡介

最近的開發平台趨勢

暫停中的計劃

開發中止的產品

產品開發的里程碑

  • 主要消息和新聞稿

附錄

圖表

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC7972IDB

Summary

Global Markets Direct's, 'Hypertension - Pipeline Review, H1 2016', provides an overview of the Hypertension pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Hypertension, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Hypertension and features dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

  • The report provides a snapshot of the global therapeutic landscape of Hypertension
  • The report reviews pipeline therapeutics for Hypertension by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved Hypertension therapeutics and enlists all their major and minor projects
  • The report assesses Hypertension therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news related to pipeline therapeutics for Hypertension

Reasons to buy

  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand important and diverse types of therapeutics under development for Hypertension
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Hypertension pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents

  • Table of Contents
  • Introduction
  • Hypertension Overview
  • Therapeutics Development
  • Hypertension - Therapeutics under Development by Companies
  • Hypertension - Therapeutics under Investigation by Universities/Institutes
  • Hypertension - Pipeline Products Glance
  • Hypertension - Products under Development by Companies
  • Hypertension - Products under Investigation by Universities/Institutes
  • Hypertension - Companies Involved in Therapeutics Development
  • Hypertension - Therapeutics Assessment
  • Drug Profiles
  • Hypertension - Recent Pipeline Updates
  • Hypertension - Dormant Projects
  • Hypertension - Discontinued Products
  • Hypertension - Product Development Milestones
  • Appendix

List of Tables

  • Number of Products under Development for Hypertension, H1 2016
  • Number of Products under Development for Hypertension - Comparative Analysis, H1 2016
  • Number of Products under Development by Companies, H1 2016
  • Number of Products under Development by Companies, H1 2016 (Contd..1)
  • Number of Products under Development by Companies, H1 2016 (Contd..2)
  • Number of Products under Development by Companies, H1 2016 (Contd..3)
  • Number of Products under Development by Companies, H1 2016 (Contd..4)
  • Number of Products under Development by Companies, H1 2016 (Contd..5)
  • Number of Products under Development by Companies, H1 2016 (Contd..6)
  • Number of Products under Development by Companies, H1 2016 (Contd..7)
  • Number of Products under Investigation by Universities/Institutes, H1 2016
  • Comparative Analysis by Late Stage Development, H1 2016
  • Comparative Analysis by Clinical Stage Development, H1 2016
  • Comparative Analysis by Early Stage Development, H1 2016
  • Products under Development by Companies, H1 2016
  • Products under Development by Companies, H1 2016 (Contd..1)
  • Products under Development by Companies, H1 2016 (Contd..2)
  • Products under Development by Companies, H1 2016 (Contd..3)
  • Products under Development by Companies, H1 2016 (Contd..4)
  • Products under Development by Companies, H1 2016 (Contd..5)
  • Products under Development by Companies, H1 2016 (Contd..6)
  • Products under Development by Companies, H1 2016 (Contd..7)
  • Products under Development by Companies, H1 2016 (Contd..8)
  • Products under Development by Companies, H1 2016 (Contd..9)
  • Products under Development by Companies, H1 2016 (Contd..10)
  • Products under Development by Companies, H1 2016 (Contd..11)
  • Products under Development by Companies, H1 2016 (Contd..12)
  • Products under Investigation by Universities/Institutes, H1 2016
  • Products under Investigation by Universities/Institutes, H1 2016 (Contd..1)
  • Hypertension - Pipeline by A1M Pharma AB, H1 2016
  • Hypertension - Pipeline by AbbVie Inc., H1 2016
  • Hypertension - Pipeline by Ache Laboratorios Farmaceuticos S/A, H1 2016
  • Hypertension - Pipeline by Actelion Ltd, H1 2016
  • Hypertension - Pipeline by Afferent Pharmaceuticals, Inc., H1 2016
  • Hypertension - Pipeline by Allergan Plc, H1 2016
  • Hypertension - Pipeline by Alnylam Pharmaceuticals, Inc., H1 2016
  • Hypertension - Pipeline by Anacor Pharmaceuticals, Inc., H1 2016
  • Hypertension - Pipeline by APT Therapeutics, Inc., H1 2016
  • Hypertension - Pipeline by Arena Pharmaceuticals, Inc., H1 2016
  • Hypertension - Pipeline by Ascendis Pharma A/S, H1 2016
  • Hypertension - Pipeline by AVEO Pharmaceuticals, Inc., H1 2016
  • Hypertension - Pipeline by Bayer AG, H1 2016
  • Hypertension - Pipeline by Bial - Portela & Ca, S.A., H1 2016
  • Hypertension - Pipeline by Bio-inRen, H1 2016
  • Hypertension - Pipeline by BioRestorative Therapies, Inc., H1 2016
  • Hypertension - Pipeline by Bristol-Myers Squibb Company, H1 2016
  • Hypertension - Pipeline by Cellceutix Corporation, H1 2016
  • Hypertension - Pipeline by Celsion Corporation, H1 2016
  • Hypertension - Pipeline by Celtaxsys, Inc., H1 2016
  • Hypertension - Pipeline by Chong Kun Dang Pharmaceutical Corp., H1 2016
  • Hypertension - Pipeline by CJ HealthCare Corp., H1 2016
  • Hypertension - Pipeline by Complexa, Inc., H1 2016
  • Hypertension - Pipeline by Conatus Pharmaceuticals Inc., H1 2016
  • Hypertension - Pipeline by Cytokinetics, Inc., H1 2016
  • Hypertension - Pipeline by Daewoong Pharmaceutical Co., Ltd., H1 2016
  • Hypertension - Pipeline by Daiichi Sankyo Company, Limited, H1 2016
  • Hypertension - Pipeline by DiaMedica Inc., H1 2016
  • Hypertension - Pipeline by Eli Lilly and Company, H1 2016
  • Hypertension - Pipeline by Esperion Therapeutics, Inc., H1 2016
  • Hypertension - Pipeline by F. Hoffmann-La Roche Ltd., H1 2016
  • Hypertension - Pipeline by Galectin Therapeutics, Inc., H1 2016
  • Hypertension - Pipeline by Genextra S.p.a., H1 2016
  • Hypertension - Pipeline by Gilead Sciences, Inc., H1 2016
  • Hypertension - Pipeline by GlaxoSmithKline Plc, H1 2016
  • Hypertension - Pipeline by Glenveigh Medical, LLC, H1 2016
  • Hypertension - Pipeline by HanAll Biopharma Co., Ltd., H1 2016
  • Hypertension - Pipeline by Hanmi Pharmaceuticals, Co. Ltd., H1 2016
  • Hypertension - Pipeline by HitGen LTD, H1 2016
  • Hypertension - Pipeline by Innopharmax Inc., H1 2016
  • Hypertension - Pipeline by Insmed Incorporated, H1 2016
  • Hypertension - Pipeline by INVENT Pharmaceuticals, Inc., H1 2016
  • Hypertension - Pipeline by Ionis Pharmaceuticals, Inc., H1 2016
  • Hypertension - Pipeline by Jeil Pharmaceutical Co., Ltd., H1 2016
  • Hypertension - Pipeline by Johnson & Johnson, H1 2016
  • Hypertension - Pipeline by JW Pharmaceutical Corporation, H1 2016
  • Hypertension - Pipeline by Kowa Company, Ltd., H1 2016
  • Hypertension - Pipeline by Lee's Pharmaceutical Holdings Limited, H1 2016
  • Hypertension - Pipeline by Les Laboratoires Servier SAS, H1 2016
  • Hypertension - Pipeline by LFB S.A., H1 2016
  • Hypertension - Pipeline by LG Life Science LTD., H1 2016
  • Hypertension - Pipeline by LinXis B.V., H1 2016
  • Hypertension - Pipeline by Lotus Pharmaceutical Co., Ltd., H1 2016
  • Hypertension - Pipeline by Mallinckrodt Plc, H1 2016
  • Hypertension - Pipeline by Mast Therapeutics, Inc., H1 2016
  • Hypertension - Pipeline by Merck & Co., Inc., H1 2016
  • Hypertension - Pipeline by Mezzion Pharma Co. Ltd., H1 2016
  • Hypertension - Pipeline by miRagen Therapeutics, Inc., H1 2016
  • Hypertension - Pipeline by Mitsubishi Tanabe Pharma Corporation, H1 2016
  • Hypertension - Pipeline by Morphogen-IX Limited, H1 2016
  • Hypertension - Pipeline by Neurim Pharmaceuticals Ltd, H1 2016
  • Hypertension - Pipeline by Nippon Kayaku Co., Ltd., H1 2016
  • Hypertension - Pipeline by Nippon Shinyaku Co., Ltd., H1 2016
  • Hypertension - Pipeline by Novartis AG, H1 2016
  • Hypertension - Pipeline by Noxamet Ltd, H1 2016
  • Hypertension - Pipeline by Omeros Corporation, H1 2016
  • Hypertension - Pipeline by Ono Pharmaceutical Co., Ltd., H1 2016
  • Hypertension - Pipeline by Peloton Therapeutics, Inc., H1 2016
  • Hypertension - Pipeline by Pfizer Inc., H1 2016
  • Hypertension - Pipeline by PhaseBio Pharmaceuticals, Inc., H1 2016
  • Hypertension - Pipeline by Pluristem Therapeutics Inc., H1 2016
  • Hypertension - Pipeline by Proteo, Inc., H1 2016
  • Hypertension - Pipeline by Pulmokine, Inc., H1 2016
  • Hypertension - Pipeline by Quantum Genomics SA, H1 2016
  • Hypertension - Pipeline by Reata Pharmaceuticals, Inc., H1 2016
  • Hypertension - Pipeline by RedHill Biopharma Ltd., H1 2016
  • Hypertension - Pipeline by Respira Therapeutics, Inc., H1 2016
  • Hypertension - Pipeline by Reviva Pharmaceuticals Inc., H1 2016
  • Hypertension - Pipeline by Sanofi, H1 2016
  • Hypertension - Pipeline by Selten Pharma, Inc, H1 2016
  • Hypertension - Pipeline by Serodus ASA, H1 2016
  • Hypertension - Pipeline by Shanghai Pharmaceutical Co., Ltd., H1 2016
  • Hypertension - Pipeline by Sihuan Pharmaceutical Holdings Group Ltd., H1 2016
  • Hypertension - Pipeline by Silence Therapeutics Plc, H1 2016
  • Hypertension - Pipeline by Simcere Pharmaceutical Group, H1 2016
  • Hypertension - Pipeline by SteadyMed Therapeutics, Inc., H1 2016
  • Hypertension - Pipeline by Suda Ltd, H1 2016
  • Hypertension - Pipeline by Sumitomo Dainippon Pharma Co., Ltd., H1 2016
  • Hypertension - Pipeline by Takeda Pharmaceutical Company Limited, H1 2016
  • Hypertension - Pipeline by The Medicines Company, H1 2016
  • Hypertension - Pipeline by Theravance Biopharma, Inc., H1 2016
  • Hypertension - Pipeline by Toray Industries, Inc., H1 2016
  • Hypertension - Pipeline by Torrent Pharmaceuticals Limited, H1 2016
  • Hypertension - Pipeline by TSH Biopharm Corporation Limited, H1 2016
  • Hypertension - Pipeline by vasopharm GmbH, H1 2016
  • Hypertension - Pipeline by VBS Pharmaceuticals, H1 2016
  • Hypertension - Pipeline by Vectura Group Plc, H1 2016
  • Hypertension - Pipeline by VG Life Sciences, Inc., H1 2016
  • Hypertension - Pipeline by Vicore Pharma AB, H1 2016
  • Hypertension - Pipeline by Yuhan Corporation, H1 2016
  • Assessment by Monotherapy Products, H1 2016
  • Assessment by Combination Products, H1 2016
  • Number of Products by Stage and Target, H1 2016
  • Number of Products by Stage and Mechanism of Action, H1 2016
  • Number of Products by Stage and Route of Administration, H1 2016
  • Number of Products by Stage and Molecule Type, H1 2016
  • Hypertension Therapeutics - Recent Pipeline Updates, H1 2016
  • Hypertension - Dormant Projects, H1 2016
  • Hypertension - Dormant Projects (Contd..1), H1 2016
  • Hypertension - Dormant Projects (Contd..2), H1 2016
  • Hypertension - Dormant Projects (Contd..3), H1 2016
  • Hypertension - Dormant Projects (Contd..4), H1 2016
  • Hypertension - Dormant Projects (Contd..5), H1 2016
  • Hypertension - Dormant Projects (Contd..6), H1 2016
  • Hypertension - Dormant Projects (Contd..7), H1 2016
  • Hypertension - Dormant Projects (Contd..8), H1 2016
  • Hypertension - Dormant Projects (Contd..9), H1 2016
  • Hypertension - Dormant Projects (Contd..10), H1 2016
  • Hypertension - Dormant Projects (Contd..11), H1 2016
  • Hypertension - Dormant Projects (Contd..12), H1 2016
  • Hypertension - Dormant Projects (Contd..13), H1 2016
  • Hypertension - Dormant Projects (Contd..14), H1 2016
  • Hypertension - Dormant Projects (Contd..15), H1 2016
  • Hypertension - Dormant Projects (Contd..16), H1 2016
  • Hypertension - Dormant Projects (Contd..17), H1 2016
  • Hypertension - Dormant Projects (Contd..18), H1 2016
  • Hypertension - Dormant Projects (Contd..19), H1 2016
  • Hypertension - Dormant Projects (Contd..20), H1 2016
  • Hypertension - Dormant Projects (Contd..21), H1 2016
  • Hypertension - Dormant Projects (Contd..22), H1 2016
  • Hypertension - Dormant Projects (Contd..23), H1 2016
  • Hypertension - Discontinued Products, H1 2016
  • Hypertension - Discontinued Products (Contd..1), H1 2016
  • Hypertension - Discontinued Products (Contd..2), H1 2016

List of Figures

  • Number of Products under Development for Hypertension, H1 2016
  • Number of Products under Development for Hypertension - Comparative Analysis, H1 2016
  • Number of Products under Development by Companies, H1 2016
  • Number of Products under Investigation by Universities/Institutes, H1 2016
  • Comparative Analysis by Late Stage Development, H1 2016
  • Comparative Analysis by Clinical Stage Development, H1 2016
  • Comparative Analysis by Early Stage Products, H1 2016
  • Assessment by Monotherapy Products, H1 2016
  • Assessment by Combination Products, H1 2016
  • Number of Products by Top 10 Targets, H1 2016
  • Number of Products by Stage and Top 10 Targets, H1 2016
  • Number of Products by Top 10 Mechanism of Actions, H1 2016
  • Number of Products by Stage and Top 10 Mechanism of Actions, H1 2016
  • Number of Products by Top 10 Routes of Administration, H1 2016
  • Number of Products by Stage and Top 10 Routes of Administration, H1 2016
  • Number of Products by Top 10 Molecule Types, H1 2016
  • Number of Products by Stage and Top 10 Molecule Types, H1 2016
Back to Top